Insider Selling: Moderna, Inc. (NASDAQ:MRNA) Director Sells 10,000 Shares of Stock

Posted by Alanna Baker on Aug 6th, 2022

Moderna, Inc. (NASDAQ:MRNA – Get Rating) Director Noubar Afeyan sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $167.99, for a total value of $1,679,900.00. Following the completion of the transaction, the director now directly owns 2,467,209 shares of the company’s stock, valued at $414,466,439.91. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Noubar Afeyan also recently made the following trade(s):

On Wednesday, July 27th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $161.00, for a total value of $1,610,000.00.
On Wednesday, July 20th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $167.00, for a total value of $1,670,000.00.
On Wednesday, July 13th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $168.88, for a total value of $1,688,800.00.
On Wednesday, July 6th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $154.85, for a total value of $1,548,500.00.
On Wednesday, June 29th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $140.47, for a total value of $1,404,700.00.
On Wednesday, June 22nd, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $127.69, for a total value of $1,276,900.00.
On Wednesday, June 8th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $147.47, for a total value of $1,474,700.00.
On Wednesday, June 1st, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $146.31, for a total value of $1,463,100.00.
On Wednesday, May 25th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $130.80, for a total value of $1,308,000.00.
On Friday, May 13th, Noubar Afeyan sold 100,000 shares of Moderna stock. The stock was sold at an average price of $134.47, for a total value of $13,447,000.00.

Moderna Price Performance

Shares of Moderna stock opened at $186.84 on Friday. Moderna, Inc. has a twelve month low of $115.61 and a twelve month high of $497.49. The stock has a market capitalization of $74.32 billion, a P/E ratio of 5.69, a PEG ratio of 1.09 and a beta of 1.61. The company has a current ratio of 1.99, a quick ratio of 1.56 and a debt-to-equity ratio of 0.04. The business’s fifty day moving average price is $152.33 and its 200 day moving average price is $152.85.

Moderna (NASDAQ:MRNA – Get Rating) last released its quarterly earnings data on Wednesday, August 3rd. The company reported $5.24 EPS for the quarter, beating the consensus estimate of $4.73 by $0.51. Moderna had a return on equity of 94.76% and a net margin of 61.12%. The company had revenue of $4.73 billion for the quarter, compared to analyst estimates of $3.95 billion. During the same period last year, the company posted $6.46 earnings per share. The firm’s revenue was up 8.7% compared to the same quarter last year. As a group, research analysts anticipate that Moderna, Inc. will post 27.35 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MRNA. Norges Bank purchased a new position in Moderna in the fourth quarter valued at about $773,229,000. Coatue Management LLC increased its position in shares of Moderna by 61.6% during the first quarter. Coatue Management LLC now owns 6,928,147 shares of the company’s stock worth $1,193,443,000 after acquiring an additional 2,641,144 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Moderna by 108.2% during the first quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock worth $657,720,000 after acquiring an additional 1,984,458 shares during the last quarter. Theleme Partners LLP increased its position in shares of Moderna by 26.2% during the first quarter. Theleme Partners LLP now owns 6,336,940 shares of the company’s stock worth $1,091,601,000 after acquiring an additional 1,314,766 shares during the last quarter. Finally, BlackRock Inc. increased its position in shares of Moderna by 3.7% during the first quarter. BlackRock Inc. now owns 28,671,935 shares of the company’s stock worth $4,939,029,000 after acquiring an additional 1,010,462 shares during the last quarter. 61.20% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Piper Sandler decreased their price objective on Moderna from $348.00 to $214.00 and set an “overweight” rating on the stock in a report on Tuesday, May 17th. Morgan Stanley decreased their price objective on Moderna from $199.00 to $197.00 and set an “equal weight” rating on the stock in a report on Thursday. Finally, SVB Leerink raised their price objective on Moderna from $70.00 to $77.00 and gave the stock an “underperform” rating in a report on Monday, August 1st. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Moderna currently has an average rating of “Hold” and a consensus target price of $226.92.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.